Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)
$6.1300
-0.2400 ( +0.82% ) 221.9K
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Market Data
Open
$6.1300
Previous close
$6.3700
Volume
221.9K
Market cap
$126.11M
Day range
$5.7300 - $6.2250
52 week range
$5.7000 - $17.8000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 03, 2024 |
4 | Insider transactions | 1 | Dec 03, 2024 |
4 | Insider transactions | 2 | Nov 27, 2024 |
4 | Insider transactions | 1 | Nov 27, 2024 |
4 | Insider transactions | 1 | Nov 27, 2024 |
4 | Insider transactions | 2 | Nov 27, 2024 |
10-k | Annual reports | 105 | Nov 27, 2024 |
4 | Insider transactions | 2 | Nov 27, 2024 |
4 | Insider transactions | 2 | Nov 27, 2024 |
4 | Insider transactions | 2 | Nov 27, 2024 |